KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
NASDAQ:IMNP
Delisted

Immune Pharmaceuticals Inc. Stock Forecast

$0.0032
+0 (+0%)
At Close: Mar 05, 2019
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Immune Pharmaceuticals Inc. stock price ended at $0.0032 on Tuesday, after losing 0%.
(Updated on Mar 05, 2019)

Sell candidate since Feb 14, 2019 Loss -53.62% PDF

No changes to the price of Immune Pharmaceuticals Inc. stock on the last trading day (Tuesday, 5th Mar 2019). During the last trading day the stock fluctuated 0% from a day low at $0.0032 to a day high of $0.0032. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Due to the high volatility and the trend direction we are not able to give forecast range for this stock.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

IMNP Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, February 19, 2019, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Immune Pharmaceuticals Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.0032 and $0.0061. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Immune Pharmaceuticals Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $0.0030. With no support from accumulated volume below today's level the risk is increased, as a drop below the support at $ may give a huge drop in the stock price.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had daily average volatility of 0%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (IMNP) For The Upcoming Trading Day Of Wednesday 6th

For the upcoming trading day on Wednesday, 6th we expect Immune Pharmaceuticals Inc. to open at $0.0032, and during the day (based on 14 day Average True Range), to move between $0.0020 and $0.0044, which gives a possible trading interval of +/-$0.0012 (+/-38.45%) up or down from last closing price. If Immune Pharmaceuticals Inc. takes out the full calculated possible swing range there will be an estimated 76.91% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $0.0034 (6.25%) than the support at $0.0030 (6.25%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Immune Pharmaceuticals Inc. stock A Buy?

Immune Pharmaceuticals Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.650 Sell Candidate Unchanged

Predicted Opening Price for Immune Pharmaceuticals Inc. of Wednesday, March 6, 2019

Fair opening price March 6, 2019 Current price
$0.0032 ( 0%) $0.0032

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for IMNP

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.0032 .
R2 0.0032 .
R1 0.0032 .
Current price: 0.0032
Support S1 0.0032 .
S2 0.0032 .
S3 0.0032 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.0039 21.88 %
R2 0.0037 15.63 %
R1 0.0034 6.25 %
Current price 0.0032
Support S1 0.0030 -6.25%
S2 0 .
S3 0 .

FAQ

What is the symbol for Immune Pharmaceuticals Inc. Stock and on which exchange is it traded?
The symbol for Immune Pharmaceuticals Inc. is IMNP and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Immune Pharmaceuticals Inc. Stock?
Immune Pharmaceuticals Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Immune Pharmaceuticals Inc. Stock?
Immune Pharmaceuticals Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Immune Pharmaceuticals Inc. Stock.

What's the current price of Immune Pharmaceuticals Inc. Stock?
As of the end of day on the Mar 05, 2019, the price of an Immune Pharmaceuticals Inc. (IMNP) share was $0.0032.

What is the 52-week high and low for Immune Pharmaceuticals Inc. Stock?
The 52-week high for Immune Pharmaceuticals Inc. Stock is $0.420 and the 52-week low is $0.0023.
Click to get the best stock tips daily for free!

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The companyÂ’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing NanoCyclo, a topical nanocapsule formulati... IMNP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT